Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 3 - What They Never Told You

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

3 Big Dividend Plays With Strong Earnings to Back Them

3 Big Dividend Plays With Strong Earnings to Back Them

Three major dividend names—Waste Management, Eversource, and Johnson & Johnson—each gave investors new reasons to keep them in mind thanks to recent earnings.

Worried About a Fading Rally? Consider These 3 Dividend Stocks

Worried About a Fading Rally? Consider These 3 Dividend Stocks

Volatility is back in the markets, and jobs data points to a weakening labor market. Is it time to get defensive? Consider these 3 dividend stocks for income.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Johnson & Johnson Stock: Analyst Estimates & Ratings

Johnson & Johnson has outpaced the broader market and the healthcare sector in 2025, and analysts remain optimistic about the stock’s prospects.

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.

4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise

With solid Q2 results and 2025 guidance increases, Wall Street is upgrading these four stocks. Analysts now see palpable upside in one streaming stalwart.

inkl

Read news from The Economist, FT, and more,
with one subscription

Want Steady Income? 3 Top Dividend Stocks for July 2025

Want Steady Income? 3 Top Dividend Stocks for July 2025

Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility

Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious

Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious

Shares of Johnson Johnson (NYSE:JNJ) are under pressure Thursday, despite a strong second-quarter earnings report.

Johnson & Johnson Analysts Raise Their Forecasts After Upbeat Earnings

Johnson & Johnson Analysts Raise Their Forecasts After Upbeat Earnings

Johnson Johnson (NYSE:JNJ) posted better-than-expected quarterly earnings and raised its FY2025 earnings guidance on Wednesday.

Johnson & Johnson Credits Tariff Delays For Strong Earnings, While Jim Cramer Pegs It On 'Lower Than Thought' Levies

Johnson & Johnson Credits Tariff Delays For Strong Earnings, While Jim Cramer Pegs It On 'Lower Than Thought' Levies

Johnson Johnson (NYSE:JNJ) delivered better-than-expected second quarter results, with the management hinting at leveraging tariff delays to maintain its outlook; however, CNBC’s Jim Cramer credited the performance to lower tariffs.

JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now

JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now

Johnson & Johnson is back in rally mode after years of post-pandemic normalization and the impact of repositioning, set up to sustain higher prices for years.

Johnson & Johnson Lifts Annual Forecast After Strong Cancer Drugs, Medtech Performance

Johnson & Johnson Lifts Annual Forecast After Strong Cancer Drugs, Medtech Performance

Johnson Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68.

Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Johnson Johnson (NYSE:JNJ) will release earnings results for the second quarter, before the opening bell on Wednesday, July 16.

Get all your
news in one place.

100's of premium titles.
One news app.

Here's What to Expect From Johnson & Johnson's Next Earnings Report

Johnson & Johnson is set to unveil its Q2 results in the upcoming month, and analysts expect its profitability to observe a notable decline.

6 Stocks to Buy to Give Your Portfolio the Perfect Mix of Growth, Value, and Defense

This blend of stocks may be the key to long-term success.

Why This Statistical Edge Favors CRWD, JNJ and LULU For the Coming Week

While narratives provide interesting context and color, empirical data delivers a quantitative advantage for astute options traders.

3 Top Dividend Stocks Analysts Are Bullish on Right Now

With earnings season coming to an end, investors are looking for new catalysts; here are three blue-chip companies with strong analyst support

Get all your
news in one place.

100's of premium titles.
One news app.

Johnson & Johnson Stock: Is JNJ Outperforming the Healthcare Sector?

Johnson & Johnson has outpaced the broader healthcare sector over the past year, and analysts remain optimistic about the stock’s prospects.

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

These defensive stocks pay reliable dividends.

3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market

For buy-and-hold investors looking for some quality names to navigate a turbulent market, here are three stocks to consider

3 Value Stocks Poised to Grow Dividends and Buybacks Now

As the U.S. and China agree to a 90-day tariff suspension, three value stocks stand out for their potential to compound returns through share buybacks and dividend growth.

3 Industry Behemoths Are Rewarding Investors With Dividend Bumps

See these three stocks that are among the most important in their industries, which have announced sizable increases in their dividends.

3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.

Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?

Johnson & Johnson had more good than bad; investors should look at the entire report in context before deciding if JNJ stock is a good fit for their portfolios

1 2 3 4 5

People

183,869 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

365,605 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play